GlassScriptPhysician profile
Charles W Clogston
NPI 1962449728
$7,287.62
in general payments reported to CMS, 2019-2025
21 companies · $866 in 2025
The $866 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,622 · 2020: $743 · 2021: $982 · 2022: $1,104 · 2023: $1,084 · 2024: $888 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,829 · Education: $9.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,828.68 |
| Education | $9.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,684.86 | 2019-2025 | |
| Pfizer INC. | $865.86 | 2019-2024 | |
| Amgen INC. | $752.68 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $707.56 | 2020-2023 | Mitraclip |
| E.R. Squibb & Sons, L.L.C. | $623.11 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $309.96 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $266.03 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $235.59 | 2020-2022 | |
| Irhythm Technologies, INC. | $197.70 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Heartflow, INC. | $136.83 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $135.19 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $126.58 | 2024 | |
| Esperion Therapeutics, INC. | $76.29 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $61.82 | 2022-2025 | Winrevair |
| Scpharmaceuticals INC. | $20.06 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $18.59 | 2024 | Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.34 | 2025 | Jardiance |
| Cardiovascular Systems INC. | $15.11 | 2020 | |
| Boston Scientific Corporation | $14.32 | 2019 | |
| Ge Healthcare | $12.10 | 2019 | |
| Gilead Sciences, INC. | $12.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Clogston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.